Extracorporeal Membrane Oxygenation System Market is expanding rapidly as Fresenius Medical Care North America Receives the U.S. FDA Clearance for its ECMO System

 Extracorporeal membrane oxygenation (ECMO) system is a life-support machine for people who have severe and life-threatening diseases of the heart and lungs. ECMO systems replace the function of lungs and hearts in the intensive care units (ICU). It is typically used to help people whose lungs cannot provide adequate oxygen to the body when extra oxygen and whose lungs cannot get rid of carbon dioxide. 

 

Increasing prevalence of cardiovascular and respiratory diseases is expected to drive growth of the global extracorporeal membrane oxygenation system market during the forecast period. According to the World Health Organization (WHO), around 31% of all deaths, which is 17.9 million worldwide are due to cardiovascular diseases (CVD). Moreover, around 85% of all CVD deaths are due to strokes and heart attacks. According to the WHO, around 65 million people suffer from the chronic obstructive pulmonary disease (COPD), while 3 million die each year. Extracorporeal membrane oxygenation system plays a critical role in CVD diseases where blood is pumped outside of the body to a heart-lung machine, which removes carbon dioxide and sends oxygen-filled blood back to tissues in the body. Thus, these factors are expected to drive growth of the global extracorporeal membrane oxygenation system market during the forecast period. Furthermore, increasing number of ECMO centers is expected to propel the global extracorporeal membrane oxygenation system market growth over the forecast period.

However, the high cost of ECMO and lack of skilled personnel operating ECMO is expected to hinder the global extracorporeal membrane oxygenation system market growth over the forecast period. Besides, rising survival rates with ECMO can present significant growth opportunities in the global extracorporeal membrane oxygenation system market in the near future. Among regions, North America is expected to witness significant growth in the global extracorporeal membrane oxygenation system market during the forecast period. This is owing to increasing prevalence of diseases and proactive government support for quality healthcare across the region. Furthermore, Asia Pacific is expected to register a robust growth rate over the forecast period, owing to robust economic development in emerging economies such as Japan, India, and China in the region.

Key companies involved in the global extracorporeal membrane oxygenation system market are Alung Technologies Inc., Xenios AG, Eurosets, Abbott Laboratories, Getinge AB, Terumo Medical Corporation, Livanova plc, Nipro Medical Corporation, Medtronic plc, and Microport Scientific Corporation.

For instance, in February 2020, Fresenius Medical Care North America received the U.S. Food and Drug Administration (FDA) approval for Novalung, an ECMO system indicated for acute respiratory or cardiopulmonary failure.